FR10024 is a broad-spectrum antibiotic. The in vitro antibacterial activity of FR10024 against clinical isolates of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis is greater than that of any of the cephalosporins developed to date. Indole-positive Proteus, Enterobacter, and Citrobacter are resistant to FR10024, as is true for the other cephalosporins. However, more than half of the strains of Enterobacter and Citrobacter tested were susceptible to FR10024 at an inoculum of 106 cells/ml. A single subcutaneous injection of FR10024 to mice with peritoneal infections due to S. aureus and several species of gram-negative bacilli gave a protective effect inferior to that of cefazolin but appeared to be superior to that of cephalothin. When given in two divided doses, however, the protective effect of FR10024 was enhanced and almost equaled that of cefazolin. The serum levels and rates of urinary recovery of FR10024 varied in different animal species. The mean peak serum level of FR10024 in humans after a single intramuscular injection of 500 mg was two times higher than that of cephalothin. The serum half-life after intramuscular injections of 250 and 500 mg was slightly shorter than that of cephalothin. After receiving 250 mg of FR10024 intramuscularly the urinary recovery rate was 87.7% in healthy volunteers. The biliary excretion rate of FR10024 was particularly high. The 24-h excretion of FR10024 in rats was 63.3%, this being six to seven times higher than that for cefazolin, which has the highest biliary excretion of the other known cephalosporins. When FR10024 was injected intramuscularly (20 mg/kg), it was found that the hepatic levels of FR10024 in rats were the highest of all the cephalosporins, including cefazolin, but the levels of FR10024 in other tissues were not as high as those of cefazolin.
In an effort to develop better cephalosporins, a great number of derivatives have been synthesized and evaluated in the Research Laboratories of Fujisawa Pharmaceutical Co., Ltd., Osaka. Cefazolin (4) and ceftezole (5) , both having excellent antibacterial activity and tolerance, were found in this screening program and both are now in clinical use. FR10024, a new cephalosporin derivative [sodium 7-(2-thienyl)acetamido-3-(1-methyltetrazol-5-yl)-thiomethyl-3-cephem-4-carboxylate] recently developed in our Research Laboratories, has proved superior in antibacterial activity to both cefazolin and ceftezole (Fig. 1) . In animal experiments with FR10024, it was found that its biliary excretion pattern was unqiue when compared with that of other known cephalosporins (1, (3) (4) (5) Subjects. The antibiotics were tested in the following subjects: (i) male ICR strain mice aged 4 weeks, each weighing 21 to 25 g; (ii) male SD strain rats aged 6 weeks, each weighing 190 to 240 g; (iii) male beagle dogs, each weighing 9.5 to 14.5 kg; (iv) male rhesus monkeys, each weighing 6.4 to 9.9 kg; (v) male healthy adult volunteers, each weighing 56 to 65 kg.
In vitro antibacterial activity. The in vitro antibacterial activity of the test antibiotics was determined by the agar dilution method (2) . One drop of an overnight broth culture and decimal dilutions thereof were inoculated on heart infusion agar (Difco) containing graded concentrations of the test drugs. The minimum inhibitory concentration (MIC) was determined after incubation at 37°C for 20 h.
Bactericidal activity. (i) MBC. Each heart infusion broth containing graded concentrations of the test antibiotics was inoculated with test organisms to obtain a concentration of about 106 cells/ml. After incubating at 37°0 for 20 h, the minimum bactericidal concentration (MBC) was determined as the lowest antibiotic concentration in which viable cell counts were decreased to less than 102 cells/ml.
(ii) Initial killing rate. Heart infusion broths containing a concentration of 10 ,ug of each of the test antibiotics per ml, were inoculated with four strains of Escherichia coli or Klebsiella pneumoniae (106 cells/ml) and were then incubated at 370C for 60 min. After inactivation with Citrobacter 3-lactamase, which destroyed the residual antibiotic in 5 min at 370C, viable cell counts in the culture fluids were measured.
Serum-protein binding. A 0.5-ml portion of the antibiotic solution (300 i,g/ml), in 0.067 M phosphate buffer (pH 7.0), was added to 4.5 ml of fresh serum and was then incubated at 370C for 1 h. This reaction liquid was poured into a Visking tube (size 8/32), suspended in a 15-ml polypropylene tube, and centrifuged at 1,000 x g for 30 min (10) . The free antibiotic concentration in the ultrafiltrate was determined by the disk method (2) . Protective effect on infections in mice. Staphylococcus aureus, E. coli, K. pneumoniae, Proteus mirabilis, and Citrobacter freundii, precultured overnight on agar slants at 370C, were suspended in a mucin solution to obtain specified cell counts of test organisms. Male ICR strain mice aged 4 weeks, each weighing 21 to 25 g, were used, and each group consisted of 10 mice. Mice were inoculated intraperitoneally with 0.5 ml of the suspension and were given a single subcutaneous dose of the test antibiotics 1 h after challenge. In another experiment, mice were given two divided doses of the test antibiotics 1 h and either 2 or 3 h after challenge. The 50% effective dose values were found by the probit method from the number of mice surviving after 2 weeks of observation.
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Serum levels. The test antibiotics were injected intramuscularly (i.m.) in animals (20 mg/kg) and in human volunteers (250 and 500 mg). The serial data on rats were obtained on the different groups used at each bleeding, and the serial data in other animals and volunteers were obtained on the same subjects throughout the test period. The antibiotic levels in each serum sample were determined by the disk method, using standard solutions prepared with animal and human sera. The serum half-life was calculated from the linear descending slope of mean antibiotic concentrations in the serum plotted se,milogarithmically against time.
Urinary excretion. Urine of rats, monkeys, and healthy volunteers was collected at specified intervals (5) after i.m. injection of the test antibiotics, 20 mg/kg in rats and monkeys and 250 and 500 mg in healthy volunteers. The antibiotic levels in each urine sample were bioassayed by the standard solutions prepared with 0.067 M phosphate buffer, pH 7.0, because there were no significant differences in standard curves between the standard solutions prepared with the buffer and those prepared with urine.
Biliary excretion. Rats and dogs anesthetized intraperitoneally with pentobarbital (25 mg/kg) were fixed in the supine position, and a polyethylene cannula was inserted into the bile duct. Bile samples were collected at 0 to 3, 3 to 6, and 6 to 24 h after i.m. injection of 20 mg of the test drugs per kg. The antibiotic levels in the bile samples were bioassayed with the standard solutions prepared with 0.067 M phosphate buffer, pH 7.0, for the same reason as in the case of urine.
Identification of active antibiotic substances in urine and bile samples. After i.m. injection of FR10024, urine samples were collected from rats, monkeys, and healthy volunteers, and bile samples were collected from rats at specified intervals. Each sample was examined by thin-layer chromatography and bioautography. For thin-layer chromatography, the following solvent was used: n-butanolacetic acid-water (4:1:2). The absorbent was Eastman chromagram sheet no. 6061. For bioautography, sheets developed with the above solvent were dried and set on the agar media, which were inoculated with 0.2% spore suspensions of Bacillus subtilis ATCC 6633 (2 x 108 spores/ml) for approximately 15 min. After the sheets were removed and the agar plate was incubated at 370C for 20 h, the bioactive substances were identified. Tissue distribution. Rats that had received 20 mg of the test antibiotics per kg were bled at set intervals and their organs were removed. After the organs were lightly washed with saline solution, the tissues were homogenized in twice their weight of ethanol with the polytron homogenizer. The antibiotic levels in the supernatant, obtained by centrifuging the homogenate at 10,000 x g for 10 min, were bioassayed with a standard solution prepared with 0.067 M phosphate buffer at pH 7.0 containing 66% ethanol, since there were no significant differences in standard curves between the standard solution with 0.067 M phosphate buffer, pH 7.0, containing 66% ethanol and the supernatant obtained from the control tissues in the same manner. The tissue levels of the test drugs were thus calculated. Table 2 ). The antibacterial activity of FR10024 against S. aureus was greater than that of cefazolin.
The MICs of FR10024 against 21 strains ofS. faecalis ranged from 25 to 50 ,ug/ml. The activity of FR10024 was almost the same as that of cefazolin and was weaker than that of cephaloridine, cephapirin, and cephacetrile. Table 3 shows the distribution of susceptibility of each of the 42 strains ofE. coli, K. pneumoniae, andP. mirabilis to the antibiotics. For E. coli, the MICs of FR10024 ranged from <0.78 to 100 ,ug/ml. The MIC was <0.78 to 6.25 jig/ml for 34 (81.0%) of the 42 strains and 12.5 to 50 Ag/ ml for 7 (16.6%) strains and was not more than 100 ,ug/ml for 1 (2.4%) strain. The antibacterial activity of FR10024 against E. coli was considered to be very similar to that of cefazolin. However, the number of strains highly susceptible to FR10024 at a MIC of 0.78 ,ug/ml or less was greater than that to cefazolin.
When the susceptibility ofK. pneumoniae to FR10024 was compared with that of the other drugs, the activity of FR10024 appeared to be greater than that of the other cephalosporins, including cefazolin. The MICs of FR10024 against 41 (97.6%) of the 42 strains were 3.13 ,g/ml or less. The MIC of the antibiotic against 19 (45.2%) highly susceptible strains was less than 0.78 ,ug/ml. The MIC against one (2.4%) strain was 50 ,ug/ml; this strain was moderately resistant. No highly resistant strains were found.
When the susceptibility of P. mirabilis to FR10024 was compared with that of other cephalosporins, including cefazolin, the MICs against 28 (66.7%) strains were not more than 6 .25 jig/ml, whereas those against 14 (33.3%) ANTIMICROB. AGENTS CHEMOTHER.
strains ranged from 12.5 to 50 ,ug/ml. No highly resistant strains were observed. FR10024 had the best antibacterial activity of all the cephalosporins tested. Table 4 shows the distribution of susceptibility of indole-positive Proteus, Enterobacter, and Citrobacter to the test antibiotics. All 20 strains of P. rettgeri were susceptible to FR10024. The MICs of FR10024 against 19 (90.5%) of the 21 strains of P. inconstans B ranged from 6.25 to 50 ,ug/ml. The MICs,.of FR10024 against 43% of E. cloacae, 62% of E. aerogenes, and 86% of Citrobacter were not more than 50 gg/ml.
Influence of various test conditions on antibacterial activity. (i) Test medium. The MIC of FR10024 against three strains was determined using five kinds of conventional agar media. No differences in antibacterial activity of FR10024 against the three strains were noted with any of the five media (Table 5) .
(ii) pH. The pH ofheart infusion agar ranged from 5.4 to 9.4, and the MIC of FR10024 against the three strains was determined. The MIC of FR10024 did not greatly fluctuate when the pH values changed.
Inoculum. Generally, the MIC of FR10024 against various test strains became correspondingly smaller when the inoculum size was reduced.
(iv) Serum. Rabbit serum (10, 20, or 50%) was added to each medium, and changes in antibacterial activity of FR10024 against the test strains were studied. The antibacterial ac- a Conditions: Heart infusion agar, stamp method, 37°C, 20 h, 106 cells/ml.
tivity of FR10024 tended to decrease when the serum was present in high concentrations. Bactericidal activity. (i) Initial killing rate. The killing rate of the specified levels (10 ,ug/ ml) of FR10024 against isolated strains of E. coli and K. pneumoniae was compared with that of the other cephalosporins. Figure 2A and B gives the mean viable cell counts at 60 min after incubation. No significant differences in the killing rate against the four strains of E. coli were noted between FR10024 and cephaloridine. The killing rate of FR10024 was slightly higher than that of cefazolin and was much higher than that ofcephalothin and cephalexin. For the four strains of K. pneumoniae, a similar pattern was observed; i.e., the killing rate was the highest for cephaloridine, followed in descending order by FR10024, cefazolin, cephalothin, and cephalexin.
(ii) MBC. The MBC and the MIC of FR10024 against 11 strains were compared with those of cefazolin and cephalothin (Table 6 ). Protective effect on infections in mice. FR10024 and the other test antibiotics were each given subcutaneously to mice 1 h after intraperitoneal infections experimentally induced by S. aureus, E. coli, K. pneumoniae, and P. mirabilis.
The in vitro antibacterial activity of FR10024 against S. aureus no. 26 was greater than that of cefazolin, but its therapeutic effect was lower (Table 6) ; the 50% effective dose value of FR10024 was greater than that ofcefazolin (35.5 mg/kg for FR10024 and 11.5 mg/kg for cefazolin). This tendency was also noted in infections with six strains of gram-negative bacilli. The MICs ofcefazolin and FR10024 againstK. pneumoniae no. 1 were both 1.56 ug/ml. The MICs of FR10024 and cefazolin against P. mirabilis no.
2 were 3.13 and 12.5 ,ug/ml, respectively. However, FR10024 was not found to be superior in therapeutic effect when compared with cefazoANrIMICRoB. AGENTS CHEMOTHER.
lin. One the other hand, the in vitro antibacterial activity of FR10024 was about eight times greater than that of cefazolin againstE. coli no. 22 and four times greater against P. mirabilis no. 22, and in these instances the therapeutic effect of FR10024 was superior to that of cefazolin.
The therapeutic effect of FR10024 after two subcutaneous injections in mice infected intraperitoneally with E. coli or C. freundii was compared with that of the other antibiotics.An mice infected with E. coli no. 22 or 29, the beneficial effect of a single injection of cephaloridine was most marked ( Table 9 ). The therapeutic effect of cephaloridine did not increase with more than one or with divided doses. However, the effect of FR10024, cefazolin, and cephalothin was greatly enhanced by dividing the dose into two equal injections. The therapeutic effect of FR10024 in divided doses was about the same as that of cefazolin and cephaloridine. FR10024 exhibited the greatest effect in mice infected with C. freundii no. 19.
Absorption and excretion: serum levels. (i) Rats. Figure 3 shows the serum levels of FR10024 and of the other cephalosporins in SD strain rats after i.m. injection of 20 mg/kg.
The serum levels of FR10024 peaked at 23.3 ,ug/ml 15 min after administration and decreased to 0.4 ,ug/ml at 2 h. The peak levels of FR10024 were nearly the same as those of cephaloridine and were about one-third those of cefazolin. The serum levels of FR10024, however, were generally higher than those of cephalothin (peak level, 14.1 ,ug/ml) and cephapirin (peak level, 14.6 ,ug/ml). The serum half-life under these conditions was the longest for cefazolin, followed in descending order by cephaloridine, FR10024, cephacetrile, cephalothin, and cephapirin.
(ii) Monkeys. Figure 4 shows the serum levels of FR10024 and the other antibiotics in monkeys after i.m. injection of 20 mg/kg. The serum levels of FR10024 peaked at 47.6 ,ug/ml at 30 min. The peak level after i.m. injection was 75.3 ug/ml for cefazolin, 35.7 ,ug/ml for cephaloridine, and 17.6 jig/ml for cephalothin. The peak level ofFR10024 was second only to cefazolin. However, the serum half-life was 33 min for FR10024, 60 min for cefazolin, and 51 min for cephaloridine. Since the half-life of FR10024 was shorter than that of the other antibiotics, the serum levels of FR10024 at 1 and 2 h after administration were commensurately lower than those of cephaloridine.
Thus, it was found that the serum levels of FR10024 after i.m. injection of 20 mg/kg varied according to the species. The serum half-life of FR10024 was short in all of the animals tested. Fig. 5 . The mean serum levels of FR10024 after administration of 250 and 500 mg peaked at 8.6 and 25.0 ,ug/ml, respectively, at 15 min. At 1 h they were 4.5 and 13.6 ,g/ml, and at 4 h they were 0.1 and 0.5 ug/ ml. FR10024 was not detectable at 6 h, except in jection of 500 mg in a crossover study. The peak level of cephalothin was 11.4 ,ug/ml at 15 min after administration, which was about one-half that of FR10024.
The serum half-life in healthy volunteers after i.m. injection was calculated from the above results to be 39 min for FR10024 and 48 min for cephalothin. (ii) Monkeys. The 24-h urinary recovery rate of FR10024 in monkeys after i.m. injection of 20 mg/kg was compared with that of the other test drugs (Table 11 ). The recovery rate of FR10024 in monkeys, unlike that in rats, was 76.6%, i.e., almost the same as that of cefazolin (80.3%) and cephaloridine (74.4%). However, the recovery rate of FR10024 varied with the species, as was the case for serum levels.
(iii) Healthy volunteers. The 24-h urinary recovery rate of FR10024 in five healthy volunteers after i.m. injection was as high as 87.7% for 250 mg and as high as 88.5% for 500 mg (Table 12 ). The peak urinary levels of FR10024 after administration were 694 ,g/ml at 0 to 2 h for 250 mg and 1,560 ,ug/ml at 0 to 2 h for 500 mg, and decreased thereafter. The majority of the 24-h excretion of FR10024 was obtained within 4 h after each i.m. injection of 250 or 500 mg. The 24-h urinary recovery rate of cephalothin in five volunteers after i.m. injection was as high as 51.2% for 500 mg; i.e., it was lower than that of FR10024.
Biliary excretion. (i) Rats. The 24-h biliary excretion rate of FR10024 after i.m. injection of 20 mg/kg was compared with that of the other cephalosporins (Table 13) (ii) Dogs. The 24-h biliary excretion rate of FR10024 in beagle dogs after i.m. injection of 20 mg/kg was 9.6% (Fig. 6) . In this experiment, the biliary excretion of FR10024 was not compared with that of other antibiotics; however, the biliary excretion of other cephalosporins in dogs is known to be comparatively low. The biliary excretion ofFR10024 was approximately three times higher than that reported previously for cefazolin. The biliary levels of FR10024 in dogs were 1,770 ,ug/ml at 1 h and 215 ,ug/ml at 6 h after administration.
Antibacterial substances in urine and bile. Using thin-layer chromatography-bioautography, the bioactive substances in the urine and bile of rats, monkeys, and healthy volunteers were investigated after i.m. injection of FR10024 (Fig. 7) . Spots of bioactive substances in the urine or bile of each animal and of humans were detected only at the positions corresponding to the standard reference for FR10024.
Tissue distribution. Table 14 shows the tissue levels of FR10024 in rats after i.m. injection of 20 mg/kg. FR10024 was distributed into all the tissues 30 min after administration. In the case of the tissue distribution ofFR10024, it was found that hepatic levels were higher than those of the other cephalosporins. At 30 min the hepatic levels were 24.9 ug/g for FR10024, 16.3 ,ug/g for cefazolin, and 8.6 ug/g for cephaloridine. Renal levels were 70.3 ,ug/g for cephaloridine, 45.4 p.g/g for cefazolin, and 28.4 ,ug/g for FR10024. Renal levels of the other cephalosporins were all lower than those of FR10024. Other tissue levels, such as of the lungs, heart, and spleen, were the highest for cefazolin, fol- Of the commercially available cephalosporins, cefazolin is known to be the drug with the highest biliary excretion (6, 9) . In our animal experiments, the 24-h biliary excretion rate after i.m. injection of 20 mg of cefazolin per kg was about 10% in rats and about 3% in dogs (3). In patients, biliary levels of cefazolin were higher than those of cephalothin and cephaloridine (6) (7) (8) (9) . In the animal experiments, the biliary excretion rate of FR10024 at the same doses averaged 63.3% in rats and 9.6% in dogs, significantly higher than that of cefazolin. These findings suggest that it will be of special inter- est to evalute the therapeutic effect of FR10024 in patients with biliary tract infections.
